MBHB Associate Taylor Weilnau on Supreme Court “Skinny Labeling” Case

In STAT, MBHB Associate Taylor Weilnau comments on the Supreme Court’s decision to review the Hikma v. Amarin case, noting that the ruling will have a “significant impact” on the pharmaceutical industry and patients. View the article.